Is Wegovy covered by Medicare?

Not for weight loss alone (excluded by federal statute), but covered under Part D for cardiovascular risk reduction in beneficiaries with established cardiovascular disease and BMI 27 or higher, based on the SELECT trial and the CMS March 2024 guidance.

Does my insurance cover Wegovy?

Call the pharmacy benefit number on the back of your card and ask for a formulary check on semaglutide 2.4 mg (Wegovy). They can tell you coverage status, tier, prior authorization criteria, and your estimated copay in one call.

Does Aetna cover Wegovy for weight loss?

Many Aetna commercial plans cover Wegovy with prior authorization requiring BMI 30+ (or 27+ with comorbidity), lifestyle modification documentation, and sometimes step therapy. Coverage depends on the specific employer's formulary; verify with the member services number on your card.

Does BCBS cover Wegovy?

Coverage varies by state and by plan. Most Blue plans that cover Wegovy require prior authorization with BMI criteria and three to twelve months of lifestyle modification documentation. Some BCBS employer plans exclude weight-loss drugs entirely.

Does Cigna cover Wegovy?

Cigna uses Express Scripts as its PBM. When covered, Cigna requires prior authorization with BMI documentation and often step therapy. Some Cigna plans apply the $200 per month Evernorth EncircleRx cap for GLP-1s.

Does CVS Caremark cover Wegovy?

CVS Caremark coverage depends on the employer's formulary choice. Some Caremark formularies cover Wegovy with prior authorization; others have excluded it entirely. Check your specific plan's drug list, not the generic Caremark formulary.

Does Humana cover Wegovy?

Humana excludes weight-loss medications across most commercial and Medicare Advantage plans. Claims typically auto-reject at the pharmacy. Coverage for the cardiovascular risk reduction indication may be possible on select Medicare plans; verify directly with Humana.

Does Kaiser Permanente cover Wegovy?

Most standard Kaiser plans do not cover Wegovy for weight loss. Coverage usually requires the employer to opt in to a GLP-1 benefit, and clinical criteria vary by Kaiser region.

Does Medicaid cover Wegovy?

Roughly a dozen state Medicaid programs cover Wegovy for chronic weight management, including California, Pennsylvania, Michigan, and Massachusetts. Most state Medicaid programs cover semaglutide (Ozempic) for type 2 diabetes but exclude Wegovy for weight loss. Verify with your state agency.

Does TRICARE cover Wegovy?

TRICARE Prime and Select can cover Wegovy with prior authorization and step therapy. Active duty members pay $0 when covered. Eligibility criteria mirror the standard BMI thresholds.

How do I get Wegovy covered if my plan denies it?

Read the denial letter for the specific reason, submit the missing documentation through prior authorization, file an internal appeal with stronger clinical evidence, escalate to external review if the internal appeals fail, and consider switching to a covered alternative (Ozempic for diabetes if applicable).

Why doesn't my insurance cover Wegovy?

Most plans that exclude Wegovy classify weight-loss medications as a non-covered benefit category, separate from the medical-necessity decision for any individual patient. The exclusion is set by the employer or plan sponsor, not by the drug manufacturer or pharmacy.

Does Wegovy require prior authorization?

Yes, on virtually every plan that covers it. More than 88% of covering plans require prior authorization, with criteria around BMI, comorbidities, lifestyle modification, and sometimes step therapy.

How much is Wegovy with insurance?

With commercial insurance that covers Wegovy and the NovoCare savings card, many patients pay $0 to $25 per fill. Without coverage, the cash price through NovoCare Pharmacy is around $499 per 28-day supply; list price is approximately $1,350.

Can my employer add Wegovy coverage even if my insurer normally excludes it?

Yes, for self-funded plans. Most large employers self-fund their health benefits and can elect to cover Wegovy regardless of the insurer's standard formulary. Ask HR or your benefits administrator whether the plan includes a GLP-1 carve-out.

Will insurance cover Wegovy for pre-diabetes?

Pre-diabetes alone is not enough. It can serve as the qualifying comorbidity if your BMI is between 27 and 29.9, but with a normal BMI and pre-diabetes alone, Wegovy is not typically covered. Metformin is the standard covered option for pre-diabetes.

Is there still a Wegovy shortage in 2026?

No. The FDA-recognized semaglutide shortage ended and all Wegovy doses are listed as available. Localized backorders at specific pharmacies still happen; call multiple pharmacies before assuming a national shortage.

Is Wegovy Covered by Insurance?

Summary: Wegovy coverage depends entirely on what your specific plan decides about anti-obesity medications, with roughly 43% of very large employer plans covering it, most ACA marketplace plans excluding it, and Medicare Part D restricted to the cardiovascular risk reduction indication.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: sometimes. Coverage for Wegovy depends almost entirely on whether your specific plan chose to include anti-obesity medications, and that choice varies dramatically by plan type. About 43% of very large employer plans (5,000+ workers) cover GLP-1s for weight loss, dropping to 30% at large employers and 16% at mid-size employers ^[4]. Most ACA marketplace plans exclude obesity drugs outright. Medicare Part D excluded weight-loss drugs by federal statute for decades, with one significant carve-out that opened in 2024 for cardiovascular risk reduction.

What follows is a plan-by-plan map of who covers Wegovy, what prior authorization typically requires, what to do if you get denied, and how the NovoCare savings program fills the gap when insurance does not.

Coverage at a glance by plan type

Plan type	Coverage likelihood	Notes
Very large employer (5,000+)	Most likely	~43% cover GLP-1s for weight loss; PA almost always required
Large employer (1,000 to 4,999)	Moderate	~30% cover
Mid-size employer (200 to 999)	Less likely	~16% cover
ACA marketplace	Rare	Fewer than 1% of marketplace plans cover obesity drugs
Medicare Part D	Excluded for weight loss	Coverage allowed only for cardiovascular risk reduction indication
Medicaid	State-by-state	About a dozen states currently cover for obesity
TRICARE	Plan-dependent	Prime and Select may cover with PA and step therapy

The single biggest predictor is the size of the employer behind a commercial plan. Self-funded plans at very large employers are the most likely to include Wegovy because those companies negotiate their own formularies directly, and many have added GLP-1 coverage in response to employee demand. Marketplace and Medicare plans operate under different rules and have historically been the toughest places to get coverage.

Commercial insurance: the plan-by-plan picture

UnitedHealthcare and OptumRx

UnitedHealthcare's coverage is genuinely plan-dependent. Employer-sponsored UHC plans vary widely; some include Wegovy on the commercial formulary with prior authorization, others have removed it. OptumRx, the UHC pharmacy benefit manager, manages the actual drug list and has shifted multiple times. Several OptumRx formularies now cover Wegovy only for the cardiovascular risk reduction indication, not for weight loss alone. If your card says UHC or Optum, do not assume either way. Call the member number on the back of the card and ask whether semaglutide injection 2.4 mg is covered, what tier, and what the prior authorization criteria are.

Blue Cross Blue Shield (Anthem, Empire, BCBSTX, and others)

There is no single BCBS policy. Each Blue plan is run by a separate licensee, and Anthem Blue Cross, BCBS of Texas, Empire BlueCross, Highmark, and the rest each set their own rules. Most BCBS plans that cover Wegovy require BMI of 30 or higher, or 27 with a weight-related comorbidity, six to twelve months of documented lifestyle modification, and prior authorization renewed annually. Anthem commercial plans frequently exclude GLP-1s for weight loss in fully-insured products but may include them in self-funded employer carve-outs. The Empire Plan (New York State public employees) has its own formulary that does include Wegovy with PA.

Cigna and Express Scripts

Cigna uses Express Scripts as its PBM. When covered, Cigna typically requires prior authorization with BMI documentation, evidence of comorbidity, and step therapy through lifestyle modification. Some Cigna plans now apply the $200 per month Evernorth EncircleRx cost cap for GLP-1s, though that program is employer-elected and not on every plan.

Aetna and CVS Caremark

Aetna prior authorization criteria, updated for 2025, require documented BMI, a weight-related comorbidity for the lower threshold, a lifestyle modification program (typically diet and physical activity logs for at least three months), and often step therapy past a less expensive anti-obesity option. CVS Caremark is the PBM for Aetna and for many self-funded employer plans not affiliated with Aetna. The Caremark formulary has excluded Wegovy entirely on some employer-elected drug lists; on others it sits on a specialty tier with PA.

Humana

Humana is the clearest "no" among major commercial insurers. Humana explicitly excludes weight-loss medications across most of its commercial and Medicare Advantage products. Claims often auto-reject at the pharmacy counter. Coverage may be possible on certain Humana Medicaid managed-care contracts in states that cover GLP-1s, but not on standard commercial plans.

Kaiser Permanente

Most standard Kaiser plans do not cover Wegovy for weight loss. Coverage typically requires an employer to opt in to a GLP-1 rider, and clinical eligibility criteria vary by Kaiser region. Members enrolled through a Kaiser federal employee plan or a large self-funded employer may have access; individual marketplace Kaiser plans usually do not.

Other plans worth checking

Harvard Pilgrim, Priority Health, UPMC Health Plan, Centene managed care, IEHP, and similar regional plans all run their own formularies. Most apply PA criteria similar to the larger insurers above. UMR is a UnitedHealth-owned third-party administrator for self-funded employer plans, so UMR coverage is whatever the employer chose. Same for Meritain (Aetna's TPA arm).

Medicare Part D and the SELECT-driven 2024 expansion

Medicare Part D explicitly excludes drugs used for "anorexia, weight loss, or weight gain" under Social Security Act section 1860D-2(e)(2)(A). That statutory exclusion is why Wegovy, Zepbound, Saxenda, and Contrave were uncovered for Medicare beneficiaries for years.

That changed in March 2024. The SELECT trial, published in NEJM in November 2023, showed that semaglutide 2.4 mg reduced the risk of a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% over a median 39.8 months in adults with established cardiovascular disease and overweight or obesity, but without diabetes ^[3]. On the strength of those results the FDA approved a new indication for Wegovy in March 2024 to reduce major adverse cardiovascular events.

Within weeks, CMS issued a memorandum clarifying that an anti-obesity medication with a separate, medically accepted indication beyond weight loss can be covered under Part D for that other indication. In practical terms, Wegovy can be covered by Medicare Part D when prescribed to reduce cardiovascular risk in a beneficiary with established cardiovascular disease and a BMI of 27 or higher ^[2]. It cannot be covered when prescribed solely for chronic weight management.

Coverage at the plan level is uneven. By late 2025 a meaningful share of Medicare Part D and Medicare Advantage prescription drug plans had added Wegovy for the CV risk reduction indication, often with prior authorization and step therapy. Costs are still high. Wegovy lands on the specialty tier in most plans, which means coinsurance of roughly 25% to 33% until the beneficiary hits the 2025 Part D out-of-pocket cap of $2,000, after which catastrophic coverage takes over and the member pays $0 for covered drugs the rest of the year.

A broader Part D coverage expansion for obesity itself is under active discussion. CMS has tested the BALANCE Model concept that would cover GLP-1s for chronic weight management at a fixed beneficiary cost (the proposed figure has been around $50 per month), with phased implementation targeted for 2027. None of that is final, and timelines have slipped before.

Ozempic, which is the same active ingredient (semaglutide) but FDA-approved for type 2 diabetes, has always been coverable under Medicare Part D when prescribed for diabetes. That is a separate question from Wegovy coverage and a common source of confusion. If you are Medicare-eligible, have type 2 diabetes, and qualify clinically, Ozempic is the right drug to discuss with your prescriber and is the version typically covered.

Medicaid: about a dozen states cover for obesity

Medicaid coverage of GLP-1s for obesity is set state by state. As of late 2025, roughly a dozen state Medicaid programs cover Wegovy or another GLP-1 for chronic weight management, with policies evolving frequently ^[5]. California (Medi-Cal), Pennsylvania, Michigan, Minnesota, North Carolina, Massachusetts, and Virginia are among the states that have expanded coverage in recent years; many others still exclude weight-loss drugs from the Medicaid drug list. Ohio Medicaid does not currently cover Wegovy for weight loss.

Medicaid coverage for diabetes (Ozempic, Mounjaro) is more uniform and is required as part of standard Medicaid drug rebate participation. Coverage for weight loss is the variable piece. Verify directly with your state Medicaid agency or your Medicaid managed-care plan, and check whether the program requires prior authorization, BMI documentation, or a step-therapy trial.

TRICARE and other federal benefits

TRICARE coverage of Wegovy depends on the plan and the indication. TRICARE Prime and TRICARE Select can cover Wegovy with prior authorization and step therapy when clinical criteria are met. Active duty members pay $0 when covered; retirees and dependents pay the standard pharmacy copay. The VA includes Wegovy on the national formulary for eligible veterans with appropriate clinical criteria. Federal Employee Health Benefits (FEHB) plans vary; BCBS Federal, GEHA, and the other carriers each set their own rules.

How to check whether your specific plan covers Wegovy

You can get a definitive answer in under fifteen minutes with two phone calls.

Find the pharmacy benefit phone number on the back of your insurance card. That number routes you to the PBM, not the medical side of the plan. Tell the agent you want a coverage check on semaglutide, brand name Wegovy, NDC if they ask. They can tell you whether it is on formulary, what tier, what the prior authorization criteria are, and what your copay or coinsurance would be.
Ask your prescriber's office to run an electronic benefit check. Most modern e-prescribing systems show real-time formulary status and PA requirements for the patient's specific plan. This is often faster and more accurate than asking the insurer because it pulls live data.
Use the NovoCare benefits verification tool at NovoCare.com. Enter your insurance details and it returns the plan's coverage status for Wegovy along with the estimated patient cost.

Look up "Wegovy" or "semaglutide" on your plan's printed formulary (your plan's website has a current PDF). Then read the Summary Plan Description, the legal document that lists what is excluded. Search it for "obesity," "weight loss," and "anti-obesity medications." If your plan has a categorical exclusion of weight-loss drugs, no prior authorization is going to override that exclusion; you need a different argument or a different drug.

Prior authorization: what insurers typically require

A typical Wegovy prior authorization request will be approved if your prescriber's submission documents the following:

BMI of 30 or higher, or BMI of 27 to 29.9 with at least one weight-related comorbidity (commonly hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
A diagnosis code that matches the indication (ICD-10 E66.x for obesity, or I-codes for the CV indication on Medicare claims)
Three to six months of documented lifestyle modification (diet, physical activity, behavioral counseling, or participation in a structured program)
For Medicare CV indication: documented history of established cardiovascular disease (prior MI, prior stroke, or established peripheral artery disease)
For plans with step therapy: evidence that the patient tried and failed, or could not tolerate, a preferred alternative such as Saxenda, Contrave, phentermine, or orlistat

Caremark and several other PBMs also ask for a baseline weight, a follow-up plan, and explicit acknowledgment that the patient will be reassessed at three to six months for response. If weight loss is below a threshold (often 5% of baseline) at the reauthorization point, coverage may not renew.

What to do if Wegovy is denied

Denials happen for predictable reasons, and most of them are fixable.

Read the denial letter

The letter must state the specific reason. The big three are: not on formulary (the drug is excluded outright), prior authorization criteria not met (you may qualify with better documentation), and step therapy required (you have to try something else first). The fix is different for each.

If it is a formulary exclusion

A formulary exclusion is the hardest denial to reverse. Your plan has decided not to cover Wegovy at all. You can still request a formulary exception, which is a separate process from a standard PA. The exception request needs your prescriber to argue that no covered alternative is medically appropriate for you. The most defensible cases involve documented failure of every covered alternative, a contraindication to the preferred alternative, or a specific clinical reason (such as the CV risk reduction indication) that the preferred alternative cannot satisfy.

If it is a PA criteria denial

Get the specific criteria in writing. Compare each item to what was actually submitted. Common gaps: lifestyle modification documentation was thin (a one-line note instead of dated visit records), comorbidity was not coded, or BMI was below the threshold by a small margin. Resubmit with the missing documentation. Plans often approve on the second submission.

If it is step therapy

You either work through the step therapy (try the preferred agent for the required period and document why it did not work for you) or you request a step therapy exception with a clinical justification. Acceptable justifications usually include a contraindication, a previously documented failure of the preferred agent, or a clinical situation where the preferred agent is not appropriate.

File an internal appeal

Every commercial plan must offer at least one level of internal appeal, and most offer two. Deadlines vary; 60 to 180 days from the denial date is typical. Submit additional clinical evidence: full visit notes, the SELECT trial citation for CV risk patients, a letter from your prescriber that addresses each criterion specifically, weight and lab trends, and any specialist input. Appeals succeed at meaningful rates when the appeal is well documented; KFF and AMA data suggest appeal success rates well above 50% across categories, though that figure varies and most patients never file.

External review

If the internal appeals fail and the denial is for a covered benefit (not a categorical exclusion), federal law gives you the right to an independent external review by a reviewer who has no financial relationship with the plan. External review decisions are binding on the insurer for medical-necessity disagreements. For ERISA self-funded plans the process is slightly different but the right exists. State insurance departments can help walk you through how to file.

Switch to the diabetes indication if applicable

If you have type 2 diabetes and your BMI alone is not getting Wegovy approved, the conversation with your prescriber may shift to Ozempic or Mounjaro for diabetes. Both are covered far more broadly across commercial plans, Medicare Part D, and Medicaid because diabetes is not subject to the weight-loss exclusion. Mounjaro (tirzepatide) is approved for type 2 diabetes; Zepbound is the same molecule approved for weight management. Coverage rules typically follow the same pattern: diabetes indications are covered widely, weight-loss indications are covered narrowly.

NovoCare savings card and cash-pay options

Novo Nordisk's NovoCare savings program is the main affordability lever for patients with commercial insurance.

Commercial insurance covers Wegovy: the savings card brings the out-of-pocket cost down by up to $225 per 28-day supply, with a maximum benefit per calendar year. Many patients pay $0 to $25 per fill.
Commercial insurance does not cover Wegovy: the card still applies in a more limited way, bringing the cost down but not to a single-digit copay. Cash price through NovoCare Pharmacy is in the $499 per month range for the all-dose offer (subject to change), which is roughly a third of the list price of about $1,350 per 28-day supply.
Government insurance (Medicare, Medicaid, TRICARE, VA): the savings card is not available. Federal anti-kickback law prohibits manufacturer copay assistance on federally funded prescriptions. Patient assistance through the Novo Nordisk Patient Assistance Program may help low-income patients meet eligibility criteria.

Telehealth platforms also offer cash-pay semaglutide. The branded Wegovy product from NovoCare Pharmacy is what we are discussing in this article; compounded semaglutide sold by telehealth companies is a different category, generally cheaper, and has its own regulatory and safety considerations. The FDA's compounding allowance during the 2023 to 2024 semaglutide shortage closed after the shortage resolved, which restricted the legal basis for many of those compounded products. Verify any compounded source against the current FDA shortage list and against your state board of pharmacy.

Shortage status as of 2026

The semaglutide shortage that disrupted Wegovy availability through much of 2023 and 2024 ended. All Wegovy doses are listed by the FDA as available, and CVS Caremark, Walgreens, and Walmart pharmacies generally have stock for in-network prescriptions. Localized backorders still happen at specific pharmacies, particularly for the 1.7 mg and 2.4 mg maintenance doses. If your pharmacy says backordered, call two or three other pharmacies before assuming it is a national shortage.

Pre-diabetes coverage

Insurance plans rarely cover Wegovy for pre-diabetes alone. The FDA-approved indications are chronic weight management in qualifying adults and adolescents and cardiovascular risk reduction. Pre-diabetes can count as the qualifying comorbidity that lets a BMI of 27 to 29.9 meet the weight-management criteria, but pre-diabetes by itself, with a normal BMI, will not get Wegovy approved. Metformin is the standard first-line option for pre-diabetes and is universally covered.

Is Wegovy covered by Medicare?: Not for weight loss alone (excluded by federal statute), but covered under Part D for cardiovascular risk reduction in beneficiaries with established cardiovascular disease and BMI 27 or higher, based on the SELECT trial and the CMS March 2024 guidance.
Does my insurance cover Wegovy?: Call the pharmacy benefit number on the back of your card and ask for a formulary check on semaglutide 2.4 mg (Wegovy). They can tell you coverage status, tier, prior authorization criteria, and your estimated copay in one call.
Does Aetna cover Wegovy for weight loss?: Many Aetna commercial plans cover Wegovy with prior authorization requiring BMI 30+ (or 27+ with comorbidity), lifestyle modification documentation, and sometimes step therapy. Coverage depends on the specific employer's formulary; verify with the member services number on your card.
Does BCBS cover Wegovy?: Coverage varies by state and by plan. Most Blue plans that cover Wegovy require prior authorization with BMI criteria and three to twelve months of lifestyle modification documentation. Some BCBS employer plans exclude weight-loss drugs entirely.
Does United Healthcare cover Wegovy?: Plan-dependent. Many UHC and OptumRx formularies now cover Wegovy specifically for the cardiovascular risk reduction indication rather than for weight loss. Check your member portal or call the number on your card.
Does Cigna cover Wegovy?: Cigna uses Express Scripts as its PBM. When covered, Cigna requires prior authorization with BMI documentation and often step therapy. Some Cigna plans apply the $200 per month Evernorth EncircleRx cap for GLP-1s.
Does CVS Caremark cover Wegovy?: CVS Caremark coverage depends on the employer's formulary choice. Some Caremark formularies cover Wegovy with prior authorization; others have excluded it entirely. Check your specific plan's drug list, not the generic Caremark formulary.
Does Humana cover Wegovy?: Humana excludes weight-loss medications across most commercial and Medicare Advantage plans. Claims typically auto-reject at the pharmacy. Coverage for the cardiovascular risk reduction indication may be possible on select Medicare plans; verify directly with Humana.
Does Kaiser Permanente cover Wegovy?: Most standard Kaiser plans do not cover Wegovy for weight loss. Coverage usually requires the employer to opt in to a GLP-1 benefit, and clinical criteria vary by Kaiser region.
Does Medicaid cover Wegovy?: Roughly a dozen state Medicaid programs cover Wegovy for chronic weight management, including California, Pennsylvania, Michigan, and Massachusetts. Most state Medicaid programs cover semaglutide (Ozempic) for type 2 diabetes but exclude Wegovy for weight loss. Verify with your state agency.
Does TRICARE cover Wegovy?: TRICARE Prime and Select can cover Wegovy with prior authorization and step therapy. Active duty members pay $0 when covered. Eligibility criteria mirror the standard BMI thresholds.
How do I get Wegovy covered if my plan denies it?: Read the denial letter for the specific reason, submit the missing documentation through prior authorization, file an internal appeal with stronger clinical evidence, escalate to external review if the internal appeals fail, and consider switching to a covered alternative (Ozempic for diabetes if applicable).
Why doesn't my insurance cover Wegovy?: Most plans that exclude Wegovy classify weight-loss medications as a non-covered benefit category, separate from the medical-necessity decision for any individual patient. The exclusion is set by the employer or plan sponsor, not by the drug manufacturer or pharmacy.
Does Wegovy require prior authorization?: Yes, on virtually every plan that covers it. More than 88% of covering plans require prior authorization, with criteria around BMI, comorbidities, lifestyle modification, and sometimes step therapy.
How much is Wegovy with insurance?: With commercial insurance that covers Wegovy and the NovoCare savings card, many patients pay $0 to $25 per fill. Without coverage, the cash price through NovoCare Pharmacy is around $499 per 28-day supply; list price is approximately $1,350.
Can my employer add Wegovy coverage even if my insurer normally excludes it?: Yes, for self-funded plans. Most large employers self-fund their health benefits and can elect to cover Wegovy regardless of the insurer's standard formulary. Ask HR or your benefits administrator whether the plan includes a GLP-1 carve-out.
Will insurance cover Wegovy for pre-diabetes?: Pre-diabetes alone is not enough. It can serve as the qualifying comorbidity if your BMI is between 27 and 29.9, but with a normal BMI and pre-diabetes alone, Wegovy is not typically covered. Metformin is the standard covered option for pre-diabetes.
Is there still a Wegovy shortage in 2026?: No. The FDA-recognized semaglutide shortage ended and all Wegovy doses are listed as available. Localized backorders at specific pharmacies still happen; call multiple pharmacies before assuming a national shortage.

The actionable summary

Coverage is winnable more often than people assume. Roughly two thirds of commercial prior authorization appeals succeed when patients file them, and fewer than one in eight ever does. If your plan covers Wegovy, get the prior authorization right the first time with full documentation. If your plan denies it, read the letter, fix the gap, and resubmit. If your plan excludes weight-loss drugs categorically, look for a different lever: the CV risk reduction indication if you qualify clinically, a switch to a diabetes indication if applicable, a self-funded employer's willingness to add coverage, or the NovoCare cash-pay route while you keep pushing. The drug is not a luxury item; the SELECT trial established a hard cardiovascular benefit, and that fact is slowly reshaping what insurers will pay for.